NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

You're absolutely right, Eagle8 — this new in vivo booster approach does not require patient-specific cell manufacturing, so there’s no need for cleanrooms or automated systems like Flaskworks. Since no cells are extracted, cultured, or reinfused, there’s no need for individualized infrastructure. Instead, the patient’s own dendritic cells are activated, matured, and “educated” entirely within the body through cytokine-conditioning regimens using biologic agents.

That said, while this avoids complex manufacturing logistics, the biologic agents themselves still need to be produced under GMP (Good Manufacturing Practice) conditions — just like any other pharmaceutical product — to ensure quality, safety, and regulatory compliance. The exact mode of administration (e.g., injection, infusion, or otherwise) has not yet been disclosed.

This in vivo approach could serve as a highly scalable and valuable complement to DCVax therapies, especially for patients who have exhausted their DCVax doses or require prolonged immune stimulation.